Polaryx Therapeutics, Inc. (PLYX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Polaryx Therapeutics, Inc. (PLYX) closed at USD 1.97 on 2026-10-14, a change of -94.4 % over the past year, with a market capitalization of USD 92.32M.

Polaryx Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Polaryx Therapeutics, Inc. key figures

Previous close

USD 1.97 (2026-10-14)

1-year change

-94.4 %

Market cap

USD 92.32M

Enterprise value

USD 85.66M

P/E ratio (trailing)

-13.93

P/E ratio (forward)

n/a

EPS (trailing)

-0.14

EPS (forward)

n/a

PEG ratio

n/a

Price to book

8.90

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.57

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Polaryx Therapeutics, Inc. and compare it with other stocks.